ArticleBMC musculoskeletal disorders2026
Diagnostic value and related factors of ultrasound-guided percutaneous needle biopsy in bone lesions suspicious for tumor.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate pathological diagnosis is essential for managing bone lesions suspicious for tumor, including primary tumors and metastases. While CT-guided biopsy is standard, it involves radiation and operational limitations. Ultrasound (US) guidance offers a radiation-free, real-time alternative but is underutilized due to signal attenuation by cortical bone. This study aims to evaluate the diagnostic value of US-guided percutaneous needle biopsy for bone lesions suspicious for tumor and identify key factors influencing its efficacy.
methodsA retrospective analysis was conducted on 345 patients with bone lesions suspicious for tumor who underwent US-guided biopsy. Parameters including soft tissue mass visibility and thickness, needle gauge (16-gauge large-bore or 21-gauge fine needle), and number of samples were recorded. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of diagnostic efficacy.
resultsThe overall diagnostic efficacy rate was 83.48%, with 79.55% for primary and 84.82% for metastatic lesions. Multivariate analysis confirmed that visible soft tissue mass (OR = 5.391), mass thickness > 15 mm (OR = 5.391), large-bore needle use (OR = 3.287), and ≥ 3 samples (OR = 0.322) were independent predictors of successful diagnosis. ROC analysis showed an AUC of 0.756. Subgroup analysis revealed optimal sampling strategies: ≥4 samples for primary and 3 for metastatic lesions.
conclusionUS-guided percutaneous needle biopsy is an effective alternative to CT guidance for bone lesions suspicious for tumor with visible soft tissue masses. Key factors improving diagnostic yield include mass thickness > 15 mm, large-bore needles, and adequate sampling. Tailored strategies based on lesion type are recommended to enhance diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.